Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

85.35
Delayed Data
As of 12:45pm ET
 +0.67 / +0.79%
Today’s Change
31.38
Today|||52-Week Range
86.92
+127.96%
Year-to-Date

Today’s Trading

Previous close84.68
Today’s open84.83
Day’s range83.51 - 86.01
Volume193,880
Average volume (3 months)969,795
Market cap$7.8B
Dividend yield--
Data as of 12:45pm ET, 08/22/2017

Growth & Valuation

Earnings growth (last year)-38.84%
Earnings growth (this year)-9.60%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+14.75%
P/E ratioNM
Price/Sales67.96
Price/Book7.91

Competitors

 Today’s
change
Today’s
% change
ALKSAlkermes Plc-0.15-0.30%
JAZZJazz Pharmaceuticals...+4.05+2.84%
SGENSeattle Genetics Inc+0.71+1.54%
TSROTESARO Inc-0.63-0.53%
Data as of 1:02pm ET, 08/22/2017

Financials

Next reporting dateNovember 8, 2017
EPS forecast (this quarter)-$1.27
Annual revenue (last year)$47.2M
Annual profit (last year)-$410.1M
Net profit margin-869.63%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts